olaptesed pegol + bendamustine + rituximab

This drug is an investigational combination therapy consisting of **olaptesed pegol** (also known as NOX-A12), **bendamustine**, and **rituximab**. Olaptesed pegol is a pegylated L-oligoribonucleotide acting as a C-X-C chemokine ligand 12 (CXCL12) inhibitor, which is designed to disrupt the tumor microenvironment and increase tumor cell sensitivity to therapy. Bendamustine is an **alkylating agent** that causes DNA crosslinking and cell death, and rituximab is a monoclonal antibody targeting CD20 on B-lymphocytes, leading to cell lysis primarily via immune mechanisms. This triple regimen has been explored in hematologic cancers, particularly relapsed/refractory diffuse large B-cell lymphoma (DLBCL), especially in patients unsuitable for intensive salvage chemotherapy or autologous transplantation[1].